WallStreetZenWallStreetZen

NASDAQ: IMRN
Immuron Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their IMRN stock forecasts and price targets.

Forecast return on equity

Is IMRN forecast to generate an efficient return?

Company
-35.06%
Industry
80.01%
Market
61.99%
IMRN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMRN forecast to generate an efficient return on assets?

Company
-29.79%
Industry
22.35%
IMRN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMRN earnings per share forecast

What is IMRN's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.02
Avg 2 year Forecast
-$0.03
Avg 3 year Forecast
-$0.01

IMRN revenue forecast

What is IMRN's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.8M-38.67%
IMRN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IMRN revenue growth forecast

How is IMRN forecast to perform vs Biotechnology companies and vs the US market?

Company
28.48%
Industry
152.36%
Market
10.68%
IMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IMRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMRN$1.67N/AN/A
CSCI$3.05N/AN/A
SNSE$0.38$4.00+947.12%Buy
BTAI$1.71$49.25+2,780.12%Buy
ERNA$0.18N/AN/A
View Top Biotech Stocks

Immuron Stock Forecast FAQ

What is IMRN's earnings growth forecast for 2025-2027?

(NASDAQ: IMRN) Immuron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.

Immuron's earnings in 2025 is -$4,624,272.On average, 1 Wall Street analyst forecast IMRN's earnings for 2025 to be -$4,559,967, with the lowest IMRN earnings forecast at -$4,559,967, and the highest IMRN earnings forecast at -$4,559,967. On average, 1 Wall Street analyst forecast IMRN's earnings for 2026 to be -$6,839,950, with the lowest IMRN earnings forecast at -$6,839,950, and the highest IMRN earnings forecast at -$6,839,950.

In 2027, IMRN is forecast to generate -$2,279,983 in earnings, with the lowest earnings forecast at -$2,279,983 and the highest earnings forecast at -$2,279,983.

If you're new to stock investing, here's how to buy Immuron stock.

What is IMRN's revenue growth forecast for 2025-2025?

(NASDAQ: IMRN) Immuron's forecast annual revenue growth rate of 28.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.68%.

Immuron's revenue in 2025 is $6,257,751.

In 2025, IMRN is forecast to generate $864,113,731 in revenue, with the lowest revenue forecast at $864,113,731 and the highest revenue forecast at $864,113,731.

What is IMRN's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: IMRN) forecast ROA is -29.79%, which is lower than the forecast US Biotechnology industry average of 22.35%.

What is IMRN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: IMRN) Immuron's current Earnings Per Share (EPS) is -$0.81. On average, analysts forecast that IMRN's EPS will be -$0.02 for 2025, with the lowest EPS forecast at -$0.02, and the highest EPS forecast at -$0.02. On average, analysts forecast that IMRN's EPS will be -$0.03 for 2026, with the lowest EPS forecast at -$0.03, and the highest EPS forecast at -$0.03. In 2027, IMRN's EPS is forecast to hit -$0.01 (min: -$0.01, max: -$0.01).

What is IMRN's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: IMRN) forecast ROE is -35.06%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.